iBio’s Machine Learning Model for Designing Engineered Epitopes Granted Patent

iBio, a company that specializes in the development of precision antibody immunotherapies, has announced that it has been issued a patent by the United States Patent and Trademark Office for its machine learning model used to design engineered epitopes. These epitopes allow for the precise steering of therapeutic antibodies toward specific regions of a target protein. According to Martin Brenner, iBio’s Chief Scientific Officer, the patent solidifies the company’s position as a leader in AI-driven drug discovery and provides it with a competitive advantage as it continues to build its pipeline of immunotherapies.

iBio’s RubrYc Discovery Engine is designed to tackle complex and challenging drug targets with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. It uses a combination of a proprietary epitope steering technology, a specialized antibody library, and AI-powered antibody optimization to quickly identify and optimize molecules that can effectively address challenging drug targets. This allows for faster discovery compared to traditional antibody discovery methods. By using machine learning to design engineered epitopes, iBio’s technology has the potential to revolutionize the way in which immunotherapies are developed, improving their effectiveness and potentially leading to better patient outcomes.

Image provided by iBio